

ALLIA.143CP3

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Zaghouani
Serial No. : 09/873,901
Filed : June 4, 2001
For : Coupling Of Peripheral Tolerance To
Endogenous IL-10 Promotes Effective
Modulation Of T Cells And Ameliorates
Autoimmune Disease
Examiner : Unknown
Group Art Unit : 1644

I hereby certify that this
correspondence and all marked
attachments are being deposited with
the United States Postal Service as first
class mail in an envelope addressed to:
Commissioner for Patents and
Trademarks, Washington, D.C. 20231,
on

November 28, 2001

Christine Hughey
Christine Hughey

RECEIVED

JAN 08 2002

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS AND TRADEMARKS
WASHINGTON, D.C. 20231

ATTN: OFFICE OF INITIAL PATENT EXAMINATION
CUSTOMER SERVICE CENTER

Sir or Madam:

Applicant hereby respectfully requests that the official Filing Receipt for the patent application listed above be corrected as follows:

Please list the Total claims as:

65

Please list the Applicant(s) as:

HABIB ZAGHOUBANI, KNOXVILLE, TN

A copy of the Filing Receipt with the corrections indicated in red ink is enclosed. Please forward the corrected filing receipt to:

Knobbe, Martens, Olson & Bear LLP
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660

Please call the undersigned at the number stated below if there are any questions concerning this filing.

Respectfully submitted,

Date: 11/28/2001

John Warst
John Warst
Registration No. 40,283
(858) 410-5174

RECEIVED

JAN 08 2002

TECH CENTER 1600/2000

COMMISSIONER FOR PATENTS

UNITED STATES PATENT AND TRADEMARK OFFICE

WASHINGTON, D.C. 20231

www.uspto.gov



UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/873,901	06/04/2001	1644	0.00	ALLIA143.CP3	45	59 65	6

CONFIRMATION NO. 5455

CORRECTED FILING RECEIPT



OC00000006498232

20995

KNOBBE MARTENS OLSON & BEAR LLP
620 NEWPORT CENTER DRIVE
SIXTEENTH FLOOR
NEWPORT BEACH, CA 92660

Date Mailed: 08/30/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Habib Zaghouani, ~~Residence Not Provided;~~
Knoxville, TN

Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/209,527 06/05/2000
AND SAID
IS A CIP OF PCT/US99/15225 07/06/1999

Foreign Applications

If Required, Foreign Filing License Granted 08/03/2001

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Title

Coupling of peripheral tolerance to endogenous IL-10 promotes effective modulation of T cells
and ameliorates autoimmune disease

Preliminary Class

530

Data entry by : RIMANDO, EMELITA

Team : OIPE

Date: 08/30/2001

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231